BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17547976)

  • 1. Relationship of botulinum dosage to duration of side effects and normal voice in adductor spasmodic dysphonia.
    Chang CY; Chabot P; Thomas JP
    Otolaryngol Head Neck Surg; 2007 Jun; 136(6):894-9. PubMed ID: 17547976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II.
    Rubin AD; Wodchis WP; Spak C; Kileny PR; Hogikyan ND
    Arch Otolaryngol Head Neck Surg; 2004 Apr; 130(4):415-20. PubMed ID: 15096423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia.
    Casserly P; Timon C
    J Laryngol Otol; 2008 Jan; 122(1):52-6. PubMed ID: 17470307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined modality treatment of adductor spasmodic dysphonia.
    Silverman EP; Garvan C; Shrivastav R; Sapienza CM
    J Voice; 2012 Jan; 26(1):77-86. PubMed ID: 21292439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.
    Meyer TK; Hu A; Hillel AD
    Laryngoscope; 2013 Nov; 123 Suppl 6():S1-14. PubMed ID: 23818277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia.
    Holden PK; Vokes DE; Taylor MB; Till JA; Crumley RL
    Ann Otol Rhinol Laryngol; 2007 Dec; 116(12):891-6. PubMed ID: 18217507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
    Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single-centre retrospective review of unilateral and bilateral Dysport injections in adductor spasmodic dysphonia.
    Elmiyeh B; Prasad VM; Upile T; Saunders N; Youl BD; Epstein R; Rubin JS
    Logoped Phoniatr Vocol; 2010 Apr; 35(1):39-44. PubMed ID: 20350075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin injection for treatment of spasmodic dysphonia: experience at Srinagarind Hospital.
    Srirompotong S; Saeseow P; Taweesaengsuksakul R; Kharmwan S; Srirompotong S
    J Med Assoc Thai; 2006 Dec; 89(12):2077-80. PubMed ID: 17214059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
    Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
    J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perceptual analyses of spasmodic dysphonia before and after treatment.
    Cannito MP; Woodson GE; Murry T; Bender B
    Arch Otolaryngol Head Neck Surg; 2004 Dec; 130(12):1393-9. PubMed ID: 15611398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
    Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
    J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin therapy for abductor spasmodic dysphonia.
    Woodson G; Hochstetler H; Murry T
    J Voice; 2006 Mar; 20(1):137-43. PubMed ID: 16126369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia.
    Adams SG; Hunt EJ; Irish JC; Charles DA; Lang AE; Durkin LC; Wong DL
    J Otolaryngol; 1995 Dec; 24(6):345-51. PubMed ID: 8699600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonpharmacologic effects of botulinum toxin on the life quality of patients with spasmodic dysphonia.
    Anari S; Carding PN; Hawthorne MR; Deakin J; Drinnan MJ
    Laryngoscope; 2007 Oct; 117(10):1888-92. PubMed ID: 17690610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot.
    Mancini F; Sandrini G; Moglia A; Nappi G; Pacchetti C
    Neurol Sci; 2005 Apr; 26(1):26-31. PubMed ID: 15877184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin injection for adductor spastic dysphonia: patient self-ratings of voice and phonatory effort after three successive injections.
    Aronson AE; McCaffrey TV; Litchy WJ; Lipton RJ
    Laryngoscope; 1993 Jun; 103(6):683-92. PubMed ID: 8502104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
    Hogikyan ND; Wodchis WP; Spak C; Kileny PR
    J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia.
    Blitzer A
    Otolaryngol Head Neck Surg; 2005 Dec; 133(6):836-8. PubMed ID: 16360499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voice handicap index results for older patients with adductor spasmodic dysphonia.
    Wingate JM; Ruddy BH; Lundy DS; Lehman J; Casiano R; Collins SP; Woodson GE; Sapienza C
    J Voice; 2005 Mar; 19(1):124-31. PubMed ID: 15766857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.